trending Market Intelligence /marketintelligence/en/news-insights/trending/i8oNM_KiM9bb1NICoWSGfQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Delaware court dismisses C.R. Bard's patent case against AngioDynamics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Delaware court dismisses C.R. Bard's patent case against AngioDynamics

AngioDynamics Inc. said the U.S. District Court for the District of Delaware dismissed C.R. Bard Inc.'s patent infringement case against the company.

The lawsuit, filed March 2015, claimed certain implantable port products made by AngioDynamics infringed on C.R. Bard's three patents. C.R. Bard, which was acquired by Becton Dickinson and Co. in a $24 billion deal, was seeking unspecified damages and other relief in the case.

AngioDynamics will maintain its focus on delivering products to its customers, the company's President and CEO Jim Clemmer said in a March 8 news release about the matter.

In May 2017, AngioDynamics filed a lawsuit against C.R. Bard for allegedly violating federal antitrust laws by tying the sales of its tip location devices with its own peripherally inserted central catheters.

Latham, N.Y.-based AngioDynamics provides minimally invasive medical devices for use in vascular access, peripheral vascular disease and oncology.